Leo Pharma brings hair loss cream into phase II

Dermatology firm Leo Pharma has begun a phase IIa trial of delgocitinib against the hair loss condition frontal fibrosing alopecia.

Photo: Leo Pharma/PR

A new clinical study will assess the safety and efficacy of Leo Pharma’s drug candidate delgocitinib in treating the hair loss condition known as frontal fibrosing alopecia, according to a registration on database Clinical Trials.

The Danish dermatology firm will recruit 35 patients who will receive either delgocitinib or a placebo cream, the registration states.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs